Open Letter to Legislators on Fetal DNA in Vaccines - Theresa Deisher

Open Letter to Legislators on Fetal DNA in Vaccines - Theresa Deisher

8 April 2019.

My name is Dr. Theresa Deisher. I am Founder and Lead Scientist of the Sound Choice Pharmaceutical Institute, whose mission is to educate the public on vaccine safety, as well as to push manufacturers to provide better and safer vaccines for the public. I graduated from Stanford University in Molecular and Cellular Physiology in 1990 and completed my postdoctoral work at the University of Washington. My career has been spent in the field of commercial biotechnology, and I have carried out basic biological and pharmacological research activities through clinical development.

I am writing about uncontested scientific facts about fetal DNA contaminants in the measles-mumps-rubella vaccine, which must be made known to lawmakers and the public.

The Merck MMR II vaccine (as well as chickenpox, Pentacel and all hepatitis-A vaccines) is produced using human fetal cell lines and is heavily contaminated with human fetal DNA from the production process. The levels in our children can reach up to 5 ng / ml after vaccination, depending on the age, weight and volume of the child's blood. This level is known to activate the Toll-like receptor 9 which can cause autoimmune attacks.

To illustrate the autoimmune ability of very small amounts of fetal DNA, consider this: labor is activated by the baby's fetal DNA that builds up in the mother's bloodstream, triggering a massive immune rejection by the baby.

This is labor.
It works like this: fetal DNA fragments of a baby with about 300 base pairs in length are found in the serum of a pregnant mother. When they reach between 0,46 and 5,08 ng / mL in serum, they activate labor through the TLR9 mechanism. The corresponding blood levels are 0,22 ng / ml and 3,12 ng / ml. Fetal DNA levels in a baby after being injected with vaccines produced by fetuses reach the same level that triggers the baby's autoimmune rejection by the mother.

Anyone who claims that the fetal DNA that contaminates our vaccines is harmless or knows nothing about immunity and Toll-like receptor or is not telling the truth.

If fetal DNA can trigger labor (a naturally desired autoimmune reaction), then those same levels in vaccines can trigger autoimmunity in a child. The fragmented fetal DNA contained in the vaccines is of similar size, ~ 215 base pairs.

This is direct biological evidence that fetal DNA contaminations in vaccines are not in low and harmless quantities. They are a very strong proinflammatory stimulus.

The administration of fragments of fetal (primitive) human DNA foreign to a child could generate an immune response that would also have a cross-reaction with the child's DNA, since the contaminating DNA could have overlapping areas very similar to the child's DNA.

Children with autistic disorder have antibodies against human DNA in circulation that non-autistic children do not have. These antibodies can be involved in autoimmune attacks in autistic children.

Duke University demonstrated in a recently conducted study in which significant improvements in behavior were observed when children with autism spectrum disorder were treated with their own autologous stored cord blood. This treatment clearly shows that most children with autism are not born with it since genetic diseases such as Down syndrome or muscle fibrosis cannot be treated with autologous stem cells.

Therefore, an environmental trigger, or more triggers, introduced into the world around 1980, when autism started to increase, must be identified and eliminated or reduced in the environment.

  • There is a strong correlation at the point of change between the increase in autism rates and the replacement in the United States 'vaccine production of animal cell lines for the rubella vaccine with human cell lines aborted in the late years.' 70.
  • The first point of change for the year of birth of the autistic disorder (AD) was identified in 1981 for data from California and the United States, preceded by a replacement in the production process:
    In January 1979, the FDA approved the replacement of rubella virus production from animal cell lines (high pass virus, HPV-77, grown e.g. in duck embryo cells) to the human fetal cell line WI-38 using the viral strain RA27 / 3
  • Both the new approved monovalent vaccine for rubella and a vaccine against mumps, measles and rubella use the fetal cell line WI-38 for the production of the part of rubella vaccine.
  • Before 1980, autism spectrum disorder was a very rare, almost unknown disease. According to CDC data, the autism rate in 2014 was 1 in 59 children, a very rapid increase since 2000, when it was 1 in 150. CDC: "The total costs per year for children with ASD in the United States states were estimated at between $ 11,5 billion - $ 60,9 billion (2011 US dollars). "
  • Recently, de novo duplications and deletions have been recognized up to 10% in simple autism spectrum disorders supporting environmental triggers on the genetics of autism spectrum disorders.
  • The rubella portion of the MMR vaccine contains fetal DNA contamination of human origin of approximately 175 ng, more than 10 times beyond the WHO recommended threshold of 10 ng per dose of vaccine.
  • No other drug on the market could obtain FDA approval without an accurate toxicity analysis (the FDA follows ICH international guidelines) -> this has never been conducted by the pharmaceutical industry for DNA contamination in the MMR vaccine.
  • Vaccines produced with human fetal cell lines contain cell debris and residual human DNA contamination, which cannot be completely eliminated during the downstream virus purification process. Furthermore, DNA is not only characterized by its sequence (ATCG), but also by its epigenetic modification (for example by the DNA methylation pattern, etc.). This accessory is highly species-specific, which is why non-human DNA will be eliminated, while this is not necessarily the case with fetal human DNA.

Injecting our children with human fetal DNA contamination carries the risk of causing two well-established diseases:

  1. Insertional mutagenesis: human fetal DNA is incorporated into the baby's DNA causing mutations. Gene therapy using homologous small fragment recombination has shown that quantities as small as 1,9 ng / ml of DNA fragments result in the insertion of stem cells into the genome in 100% of the injected mice. The levels of human fetal DNA fragments in our children after vaccination with MMR, Varivax (chicken pox) or hepatitis A vaccines reach levels above 1,9 ng / ml.
  2. Autoimmune disease: fetal human DNA Stimulates the immune system's reaction to attack the body of the baby

An additional problem: retrovirus contamination. The endogenous human retrovirus K (HERVK) is a contaminant of the measles / mumps / rubella vaccine.

HERVK can be reactivated in humans. Coding for a protein (integrase) specialized in the integration of DNA into the human genome.

Several autoimmune diseases have been associated with HERVK's activity.

It is also in the same retrovirus family as the Moloney Murine Leukemia Virus (MMLV) used in a gene therapy study, where inappropriate gene insertion (insertional mutagenesis) led to subsequent further somatic mutations and cancer in 4 out of 9 children .

It is therefore possible that the fragment of the HERVK gene present in the MMR vaccine is active, coding for the integrase or for the envelope protein, and therefore has the potential to induce gene insertion, promoting insertional mutagenesis and autoimmunity . The presence of high levels of high-level contaminating fetal DNA and HERVK contamination in the MMR vaccine is an undeveloped risk with enormous implications and dangers for public and individual health.

Solution: Forcing manufacturers to return to rubella vaccines derived from animal cell lines as has been successfully done in Japan:

  • Based on Takahashi strains of live attenuated rubella virus, produced on rabbit kidney cells. A single dose of this vaccine has recently been shown to hold immunity for at least 10 years when rubella was under regional control.
  • Divide the MMR vaccine into three options offered individually as made in Japan. The production process of the MMR vaccine needs to be modified to address and eliminate risks for the public.

Thanks for your consideration. I will be happy to answer any questions you may have about the above.

Best regards,
Theresa A. Deisher, Ph.D.


Final Notes

1749 Dexter Ave. N. Seattle, WA 98109 (206) -906-9922
www.soundchoice.org

  1. Lo et al. Am J Hum Genet. 1998 Apr; 62 (4): 768-75
  2. Enninga et al. Front Immunol. 2015 Aug 26; 6: 424
  3. Deisher et al. Issues Law Med. 2015 Spring; 30 (1): 47-70
  4. Mostafa et al. 2014, J Neuroimmunol, Vol. 272, pp. 94-98; Mostafa et al. 2015, J Neuroimmunol, Vol. 280, pp. 16-20
  5. Dawson et al. Stem Cells Transl Med. 2017 May; 6 (5): 1332-1339
  6. vi Deisher et al. Issues Law Med, 2015 Vol. 30, pp. 25-46
  7. https://www.cdc.gov/vaccines/pubs/pinkbook/rubella.html; Plotkin, SA. 2006, Clinical Infectious Diseases, Vol. 43, pp. S164-168;
  8. https://www.cdc.gov/ncbddd/autism/data.html
  9. Sebat et al. 2007, Science., Vol. 316, pp. 445-449; Sanders et al. 2011, Neuron, Vol. 70, pp.
    863 - 885
  10. Series, WHO Technical Report. WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION 941; Deisher et al. Issues Law Med. 2015 Spring; 30 (1): 47-70
  11. Kramberger et al. Hum Vaccin Immunother. 2015; 11 (4): 1010-21.
  12. McNeer, NA et al. "Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo." Gene therapy vol. 20,6 (2012): 658-69. doi: 10.1038 / gt.2012.82
  13. Victoria et al. J Virol. 2010, Vol. 84, pp. 6033-6040
  14. Lee et al. PLoS Pathog. 2007 3 (1): e10; Dewannieux et al. Biologicals, Vol. 38, pp.
    366 - 70
  15. Taietal.9, Nov2008, Mult Scler, Vol. 14, pp. 1175-80; Dickerson et al. 2008, Schizophr
    Res. 2008 Sep; 104 (1-3): 121-6, Vol. 104, pp. 121-6
  16. Hacein-Bey-Abina et al. J Clin Invest. 2008 Sep; 118 (9): 3132-42
  17. Jpn J Infect Dis. 2016 May 20; 69 (3): 221-3

Davide Suriaci Translation